Weight Gain and Antipsychotics
J Clin Psychiatry 2005;66(7):950-951 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.
The recent (November 2004) Commentary by Kane
provides readers with a comprehensive overview of the
current situation with regard to the controversy surrounding
the association of adverse metabolic effects with atypical antipsychotic
drugs. The discussion reported in the Commentary
was a response to a recently published consensus statement,2
as well as the U.S. Food and Drug Administration’s suggested
changes to labeling, and was intended to advise clinicians how
these recommendations may affect their clinical practice.
The panel of experts correctly identify the important areas
of uncertainty related to this topic, and they highlight the need
for further rigorous studies designed to examine the differential
effects of individual atypical agents.